genta inc (GNTAQ:OTC US)
genta inc (GNTAQ) Snapshot
|
Open
$0.0001
|
Previous Close
$0.0001
|
|
|
Day High
$0.0002
|
Day Low
$0.0001
|
|
|
52 Week High
08/1/12 - $0.0014
|
52 Week Low
05/23/13 - $0.0001
|
|
|
Market Cap
1.2M
|
Average Volume 10 Days
1.0M
|
|
|
EPS TTM
$-0.21
|
Shares Outstanding
6.0B
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
genta inc (GNTAQ) Related Businessweek News
No Related Businessweek News Foundgenta inc (GNTAQ) Details
Genta Incorporated, a biopharmaceutical company, engages in the identification, development, and commercialization of novel drugs for the treatment of cancer and related diseases. Its products include Tesetaxel, a novel taxane compound that has completed Phase 2 trials in patients with advanced gastric cancer, breast cancer, bladder cancer, prostate cancer, and melanoma. The company is also developing G4544a, an orally bioavailable gallium-containing compound, which has completed a single-dose Phase 1 clinical study for the treatment of diseases associated with accelerated bone loss. In addition, it markets Ganite, an intravenous formulation of gallium nitrate to treat cancer-related hypercalcemia that is resistant to hydration. The company was founded in 1988 and is based in Berkeley Heights, New Jersey. On August 3, 2012, Genta Incorporated filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware, Delaware.
genta inc (GNTAQ) Top Compensated Officers
genta inc (GNTAQ) Key Developments
On July 30, 2012, Genta Incorporated announced that it has received formal notice from the drug regulatory authority of the People's Republic of China (SFDA) that the company has received approval to start clinical trials with tesetaxel, its lead clinical compound, in China. SFDA has requested and approved a dose-ranging study of the combination of capecitabine plus tesetaxel, up to and including the dose used in a pivotal randomized trial (known as TESEGAST), as well as subsequent participation by China in the TESEGAST study. The TESEGAST study is designed to evaluate the safety and activity of tesetaxel plus capecitabine compared with capecitabine plus placebo in patients with advanced gastric cancer. Gastric cancer is the second most common tumor type in China.
Genta Incorporated restated earnings results for the first quarter ended March 31, 2012. For the period, the company restated net loss was $10,664,000 or $0.01 basic and diluted per share against net income of $5,234,000 as reported.
Genta Incorporated announced that they will report Q2, 2012 results on Aug 13, 2012
| Recently Viewed | |||
| GNTAQ:US | $0.00 USD | 0.0001 |  |
| Company | Last | Change | |
| No competitor information is available for GNTAQ. | |||
| View Industry Companies | |||
Industry Analysis
GNTAQ
Industry Average
| Valuation | GNTAQ | Industry Range |
| No financial data is available for GNTAQ. | ||
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact GENTA INC, please visit www.genta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
